Last updated on July 2018

Non-interventional Study to Assess Adherence to Treatment for Patients With Relapsing Multiple Sclerosis


Brief description of study

This is an open label, non randomized, uncontrolled, multicenter, single arm observational study. In this study, the enrolled subjects will be treated with Rebif human serum albumin (HSA)-free formulation (with or without RebiSmart) 44 microgram (mcg), subcutaneous (sc), thrice in a week (tiw) for 24 months.

Clinical Study Identifier: NCT02921035

Contact Investigators or Research Sites near you

Start Over
Sorry. There are no research Sites conducting this study in the radius provided. ( View all Sites )